Staphylococcus aureus bacteremia secondary to severe erlotinib skin toxicity

Clinical Lung Cancer

Volumn 9, Issue 1, 2008, Pages 59-60

  Grenader, Tal ^a   Gipps, Maya ^a   Goldberg, Anthony ^a  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

Author keywords

Epidermal growth factor receptor; Non small cell lung cancer; Vancomycin

Indexed keywords

ACETYLSALICYLIC ACID; CEFUROXIME; ENALAPRIL; ERLOTINIB;

ADULT; ANAMNESIS; ARTICLE; BACTEREMIA; BIOPSY; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MALE; PLEURA EFFUSION; SKIN TOXICITY; STAPHYLOCOCCUS AUREUS;

EID: 39149092376     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2008.n.010     Document Type: Article

References (11)

1. Jost M, Kari C, Rodeck U. The EGF receptor - an essential regulator of multiple epidermal functions. Eur J Dermatol 2000; 10:505-10.
2. Han SW, Kim TY, Hwang PG, et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2005; 23:2493-501.
3. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353:123-32.
4. Agero AL, Dusza SW, Benvenuto-Andrade C, et al. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 2006; 55:657-70.
5. Pérez-Soler R, Delord JP, Halpern A, et al. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist 2005; 10:345-56.
6. Herbst RS, LoRusso PM, Purdom M, et al. Dermatologic side effects associated with gefitinib therapy: clinical experience and management. Clin Lung Cancer 2003; 4:366-9.
7. Jacot W, Bessis D, Jorda E, et al. Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours. Br J Dermatol 2004; 151:238-41.
8. Busam KJ, Capodieci P, Motzer R, et al. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 2001; 144:1169-76.
9. Schwartz R, Das-Young LR, Ramirez-Ronda C, et al. Current and future management of serious skin and skin-structure infections. Am J Med 1996; 100(suppl 6A):90S-5S.
10. Hanifin JM, Rogge JL. Staphylococcal infections in patients with atopic dermatitis. Arch Dermatol 1977; 113:1383-6.
11. Trilla A, Miro JM. Identifying high risk patients for Staphylococcus aureus infections: skin and soft tissue infections. J Chemother 1995; 7(suppl 3):37-43.